Dr. Matthew T Witkowski

Dr. Matthew T Witkowski is a faculty member at the University of Colorado Anschutz Medical Campus specializing in B cell acute lymphoblastic leukemia (B-ALL) research. His work focuses on understanding mechanisms that regulate CD19 expression, which is critical for CAR-T cell therapy and bispecific T cell engager therapeutics like blinatumomab. Dr. Witkowski's research utilizes genome-wide CRISPR-Cas9 screening approaches to identify modulators of CD19 abundance on human B-ALL blasts. His work has identified key roles for transcriptional activators and RNA-binding proteins in regulating CD19 expression, with implications for overcoming antigen escape in immunotherapy.